David Bing Zhen, MD, University of Washington Medicine, Seattle, WA, discusses the future development CAR-T cells in gastric cancers. Targeting claudin 18.2 has proven to be a promising avenue for cellular therapies and early clinical trials have demonstrated promising efficacy and safety. However, additional trials are needed to confirm these findings, and to assess T cell persistence, as well as novel biomarkers of efficacy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.